摘要
目的探讨培美曲塞联合顺铂治疗晚期非小细胞肺癌患者的临床疗效。方法将90例晚期非小细胞肺癌患者根据治疗方式的不同分为对照组(n=45)和观察组(n=45),对照组采取吉西他滨联合顺铂化疗方案,观察组采取培美曲塞联合顺铂化疗方案。比较两组患者临床疗效、血清肿瘤标志物、生活质量以及不良反应发生情况。结果观察组患者总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者血清癌胚抗原(CEA)、糖类抗原125(CA125)、神经元特异性烯醇化酶(NSE)水平均较治疗前降低,且观察组患者血清CEA、CA125、NSE水平均低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组患者躯体功能、情绪功能、社会功能、认知功能、总生活质量评分均较治疗前升高,且观察组患者躯体功能、情绪功能、社会功能、认知功能、总生活质量评分均高于对照组,差异均有统计学意义(P<0.05)。观察组患者白细胞减少、恶心呕吐、肝功能损伤、皮疹发生率均低于对照组,差异均有统计学意义(P<0.05)。结论培美曲塞联合顺铂化疗能够提高晚期非小细胞肺癌患者的临床疗效,降低血清CEA、CA125、NSE水平,改善患者生活质量,且不良反应轻,安全性更高。
Objective To investigate the clinical efficacy of pemetrexed combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer.Method A total of 90 patients with advanced non-small cell lung can-cer were divided into control group(n=45)and observation group(n=45)according to different treatment methods.The control group was treated with gemcitabine combined with cisplatin chemotherapy,and the observation group was treated with pemetrexed combined with cisplatin chemotherapy.The clinical efficacy,serum tumor markers,quality of life,and occurrence of adverse events were compared between the two groups.Result The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After the treat-ment,the levels of serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),and neuron specific eno-lase(NSE)in the two groups were lower than those before the treatment,and the serum levels of CEA,CA125,and NSE in the observation group were significantly lower than those in the control group,and the differences were statistically sig-nificant(P<0.05).After the treatment,the scores of physical function,emotional function,social function,cognitive func-tion,and total quality of life in the two groups were higher than those before the treatment,and the foregoing scores in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The incidences of leukopenia,nausea and vomiting,liver function damage,and rash in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Pemetrexed com-bined with cisplatin chemotherapy could improve the clinical efficacy of patients with advanced non-small cell lung can-cer and reduce the levels of serum CEA,CA125,and NSE.It could also improve the quality of life of patients and has mild adverse events with higher safety.
作者
张娟娟
马威
马超楠
ZHANG Juanjuan;MA Wei;MA Chaonan(Department of Respiratory and Critical Care Medicine,Huaihe Hospital of He’nan University,Kaifeng 475000,He’nan,China)
出处
《癌症进展》
2023年第11期1265-1268,共4页
Oncology Progress
关键词
非小细胞肺癌
培美曲塞
顺铂
临床疗效
non-small cell lung cancer
pemetrexed
cisplatin
clinical efficacy
